Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment

Status:
Completed

Trial end date:
2010-04-27

Target enrollment:

Participant gender:

The purpose of this study is to characterize the safety and tolerability of single doses of compound 1278863A in subjects with renal impairment.

Phase 1

GlaxoSmithKline